Nesrin Karahan, Özge Çoban, Şeyda Toprak Çelenay, Oğuzhan Mete

Kutanöz Allodinisi Olan ve Olmayan Migren Hastalarında Ağrı Şiddeti, Uyku Kalitesi ve Psikolojik Durumun Karşılaştırılması

Amaç: Bu çalışmada kutanöz allodinisi (KA) olan ve olmayan migren hastalarının ağrı şiddeti,uyku kalitesi ve psikolojik durumunu karşılaştırmak amaçlanmıştır.Gereç ve Yöntemler: Çalışma bir vaka kontrol çalışması olarak tasarlandı ve 32 migren hastası içerdi. Hastalar Allodini Semptom Kontrol Listesi’ne göre KA’sı olanlar (n=16) ve olmayanlar(n=16) olmak üzere iki gruba ayrıldı. Ağrı şiddeti Görsel Analog Skala (GAS) ile, uyku kalitesiPittsburgh Uyku Kalitesi İndeksi (PUKİ) ile, psikolojik durum Hastane Anksiyete (HAD-A) ve Depresyon Ölçeği (HAD-D) ile değerlendirildi.Bulgular: KA grubunda 6 (%37,5) hastada ciddi, 5 (%31,2) hastada orta, 5 (%31,2) hastada hafifderecede KA vardı. Kontrol grubunda 1 (%6,2) hastada hafif, 10 (%62,5) hastada orta, 5 (%31,2)hastada ciddi şiddette ağrı gözlendi. KA grubunda ise 8 (%50) hastada orta ve 8 (%50) hastada ciddi şiddette ağrı vardı. KA’lı bireylerin KA’lı olmayanlara göre GAS (p=0,005), HAD-A(p=0,034) ve PUKİ skorlarının (p=0,028) daha yüksek olduğu görüldü. İki grubun HAD-D skorlarıise benzerdi (p=0,089).Tartışma ve Sonuç: KA’sı olmayan migren hastalarına kıyasla, KA’lı migren hastalarında ağrı şiddeti ve anksiyete düzeylerinin daha yüksek olduğu ve uyku kalitesinin bozulduğu görüldü. KA’lımigren hastalarında tedavi planlanırken ağrı şiddetinin yanı sıra uyku kalitesinin ve psikolojikdurumun da göz önünde bulundurulması önemlidir

A Comparison of Pain Severity, Sleep Quality, and Psychological Status between Migraine Patients with and without Cutaneous Allodynia

Aim: In this study, we aimed to compare the pain severity, sleep quality, and psychological status in migraine patients with and without cutaneous allodynia (CA). Materials and Methods: The study was designed as a case-controlled study and included a total of 32 patients with migraine. Using the Allodynia Symptom Checklist, the patients were divided into two groups: those with CA (n=16) and without CA (n=16). Pain intensity and sleep quality were assessed with the Visual Analog Scale (VAS) and the Pittsburgh Sleep Quality Index (PSQI), respectively. Psychological status was assessed using the Hospital Anxiety (HAD-A) and Depression (HAD-D) Scale. Results: Of the patients with CA, 6 (37.5%) had severe, 5 (31.2%) had moderate, and 5 (31.2%) had mild CA. Of the controls without CA, 1 (6.2%) had mild, 10 (62.5%) had moderate, and 5 (31.2%) had severe pain. In the CA group, 8 (50%) patients had moderate and 8 (50%) patients had severe pain. It was observed that VAS (p=0.005), HAD-A (p=0.034), and PSQI (p=0.028) scores were higher in individuals with CA, while HAD-D scores were similar in the two groups (p=0.089). Discussion and Conclusion: It was observed that migraine patients with CA had higher levels of pain severity and anxiety and impaired sleep quality, compared to those without CA. In migraine patients with CA, it is important that treatment planning include evaluations of sleep quality and psychological status, as well as assessments of pain severity.

PDF

___

1. Arnold M. Headache Classification Committee of the International Headache Society (IHS), The International Classification of Headache Disorders, 3rd Edition. Cephalalgia. 2018;38(1):1–211.
2. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17(1):104.
3. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, ve ark. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148–58.
4. Woolf CJ, Wall PD. Relative effectiveness of C primary afferent fibers of different origins in evoking a prolonged facilitation of the flexor reflex in the rat. J Neurosci. 1986;6(5):1433–42.
5. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123(Pt 8):1703–9.
6. Sessle BJ, Hu JW, Amano N, Zhong G. Convergence of cutaneous, tooth pulp, visceral, neck and muscle afferents onto nociceptive and non-nociceptive neurones in trigeminal subnucleus caudalis (medullary dorsal horn) and its implications for referred pain. Pain. 1986;27(2):219–35.
7. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46(9):1334–43.
8. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27(11):1293–300.
9. DaSilva AF, Nascimento TD, Jassar H, Heffernan J, Toback RL, Lucas S, ve ark. Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo. Neurology. 2017;88(17):1634–41.
10. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010;16(3):e1–e17.
11. Koyama Y. Regulation of sleep and wakefulness through the monoaminergic and cholinergic systems. Brain Nerve. 2012;64(6):601–10.
12. Yalin OÖ, Uludüz D, Sungur MA, Sart H, Özge A. Identification of allodynic migraine patients with the Turkish version of the Allodynia Symptom Checklist: reliability and consistency study. Noro Psikiyatr Ars. 2017;54(3):260.
13. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology. 2005;65(9):1419–22.
14. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983;16(1):87–101.
15. Karcioglu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the pain scales in adults: which to use? Am J Emerg Med. 2018;36(4):707–14.
16. Agargun M. Pittsburgh Uyku Kalitesi İndeksi’nin geçerliği ve güvenirliği. Turk Psikiyatri Derg. 1996;7:107–15.
17. Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
18. Aydemir O. Hastane Anksiyete ve Depresyon Ölçeği Türkçe formunun geçerlilik ve güvenilirliği. Turk Psikiyatri Derg. 1997;8:187–280.
19. Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes. 2003;1(1):29.
20. Staud R, Smitherman ML. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache R. 2002;6(4):259–66.
21. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs. 2004;18(6):337–42.
22. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007;26(4):465–73.
23. Nijs J, Malfliet A, Ickmans K, Baert I, Meeus M. Treatment of central sensitization in patients with “unexplained” chronic pain: an update. Expert Opin Pharmacother. 2014;15(12):1671–83.
24. Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Giani C, Zbinden AM, Radanov BP. Central hypersensitivity in chronic pain after whiplash injury. Clin J Pain. 2001;17(4):306–15.
25. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology. 2004;63(5):848–52.
26. Lovati C, D’Amico D, Bertora P, Raimondi E, Rosa S, Zardoni M, ve ark. Correlation between presence of allodynia and sleep quality in migraineurs. Neurol Sci. 2010;31(ek 1):S155–8.
27. De Tommaso M, Delussi M, Vecchio E, Sciruicchio V, Invitto S, Livrea P. Sleep features and central sensitization symptoms in primary headache patients. J Headache Pain. 2014;15:64.
28. Inamorato E, Minatti-Hannuch SN, Zukerman E. The role of sleep in migraine attacks. Arq Neuropsiquiatr. 1993;51(4):429–32.
29. Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ. The hypocretin/orexin system. J Roy Soc Med. 2002;95(5):227–30.
30. Yamamoto T, Nozaki-Taguchi N, Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br J Pharmacol. 2002;137(2):170–6.
31. Odo M, Koh K, Takada T, Yamashita A, Narita M, Kuzumaki N, ve ark. Changes in circadian rhythm for mRNA expression of melatonin 1A and 1B receptors in the hypothalamus under a neuropathic pain-like state. Synapse. 2014;68(4):153–8.
32. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression: is the association specific to migraine? Neurology. 2000;54(2):308–13.
33. Kao CH, Wang SJ, Tsai CF, Chen SP, Wang YF, Fuh JL. Psychiatric comorbidities in allodynic migraineurs. Cephalalgia. 2014;34(3):211–8.
34. Mendonca MD, Caetano A, Viana-Baptista M. Association of depressive symptoms with allodynia in patients with migraine: a cross-sectional study. Cephalalgia. 2016;36(11):1077–81.